Consolidated Financial Results for the First Quarter of Fiscal Year 2026(IFRS)

August 6, 2026

Name of the listed company: **NIPPON SHINYAKU CO., LTD.** Listing stock exchange: Tokyo
Code No.: 4516 URL https://www.nippon-shinyaku.co.jp/
Representative: Toru Nakai, President and Representative Director
Contact: Kenji Ban, Department Manager and Finance & Accounting Dept. Tel. +81-75-321-9116
Scheduled start of payment: ―
Supplementary material: Yes
Financial result meeting: Yes (for institutional investors and securities analysts on conference call)

* All amounts are rounded down to the nearest million yen.

1. Consolidated Financial Results for the Three Months Ended June 30, 2026 (April 1, 2026 to June 30, 2026)

(1) Operating results (¥ million)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Comprehensive income	
		%		%		%		%		%		%
Three months ended June 30, 2026	49,066	24.1	12,311	22.1	12,959	23.4	10,108	22.4	10,109	22.5	8,020	(7.3)
Three months ended June 30, 2025	39,546	1.1	10,081	(9.0)	10,504	(7.9)	8,256	(19.6)	8,255	(19.6)	8,648	(22.1)

	Earnings per share (¥)	
	Basic	Diluted
Three months ended June 30, 2026	149.98	149.98
Three months ended June 30, 2025	122.52	122.52

(2) Financial position (¥ million)

	Total assets	Total equity	Total equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
As of June 30, 2026	345,153	295,730	295,411	85.6%
As of March 31, 2026	346,359	291,871	291,551	84.2%

2. Dividends

	Annual dividends per share (¥)				
	1st quarter	2nd quarter	3rd quarter	Year-end	Annual
Year ended March 31, 2026	―	62.00	―	62.00	124.00
Year ending March 31, 2027	―				
Year ending March 31, 2027 (forecast)		62.00	―	62.00	124.00

3. Business Forecast for the Year Ending March 31, 2027 (April 1, 2026 to March 31, 2027)

(¥ million)

	Revenue		Operating profit		Profit before tax		Profit attributable to owners of parent		Basic earnings per share (¥)
		%		%		%		%	
First-half period	95,000	19.3	17,500	(10.6)	17,800	(11.1)	14,000	(11.2)	207.71
Full term	200,000	17.1	38,000	7.1	38,600	5.9	30,300	1.9	449.55

4. Others

(1) Changes in the scope of consolidation

Inclusion: None

Exclusion: None

(2) Changes in accounting policies and accounting estimates, and restatement

1. Changes in accounting policies arising from revision of accounting standards: None
2. Changes in accounting policies arising from other factors: None
3. Changes in accounting estimates: None

(3) Number of shares outstanding (ordinary shares)

Number of shares outstanding (including treasury stock)	
As of June 30, 2026:	70,251,484 shares
As of March 31, 2026:	70,251,484 shares
Number of shares of treasury stock	
As of June 30, 2026:	2,850,555 shares
As of March 31, 2026:	2,850,555 shares
Average number of shares outstanding (total for the consolidated period)	
As of June 30, 2026:	67,357,824 shares
As of June 30, 2025:	67,378,645 shares

※Review of the attached condensed interim consolidated financial statements by certified public accountants or an audit firm: Yes (voluntary)

※Explanation of appropriate use of earnings forecasts and other special notes (Cautionary statement regarding forward-looking statements, etc.)

This financial release contains certain statements about the future, which are based on information available and deemed reasonable to Nippon Shinyaku at the time of announcement, and are not the commitments made by Nippon Shinyaku.

Readers are advised that actual results may differ substantially from the above forecasts due to various unforeseeable factors.

※This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

5. Consolidated Financial Statement

(1) Consolidated Balance Sheet

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and cash equivalents	76,592	72,699
Trade and other receivables	46,157	50,567
Inventories	51,595	51,168
Other financial assets	2,414	2,425
Other current assets	6,326	6,313
Total current assets	183,086	183,175
Non-current assets		
Property, plant and equipment	34,954	35,216
Intangible assets	48,242	49,970
Right-of-use assets	2,588	2,578
Other financial assets	67,356	64,143
Deferred tax assets	6,957	6,957
Other non-current assets	3,172	3,111
Total non-current assets	163,272	161,978
Total assets	346,359	345,153

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	26,132	24,956
Other financial liabilities	273	246
Lease liabilities	913	1,452
Income taxes payable	6,979	2,850
Other current liabilities	7,806	9,837
Total current liabilities	42,105	39,343
Non-current liabilities		
Other financial liabilities	235	235
Lease liabilities	1,654	1,106
Retirement benefit liability	4,557	4,158
Deferred tax liabilities	5,875	4,519
Other non-current liabilities	59	59
Total non-current liabilities	12,382	10,079
Total liabilities	54,488	49,423
Equity		
Share capital	5,174	5,174
Capital surplus	4,547	4,564
Retained earnings	246,691	252,622
Treasury shares	(2,440)	(2,440)
Other components of equity	37,578	35,490
Total equity attributable to owners of parent	291,551	295,411
Non-controlling interests	319	318
Total equity	291,871	295,730
Total liabilities and equity	346,359	345,153

(2) Consolidated Statements of Income

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Revenue	39,546	49,066
Cost of sales	12,655	17,726
Gross profit	26,890	31,340
Selling, general and administrative expenses	9,995	11,075
Research and development expenses	6,189	9,197
Other income	169	1,364
Other expenses	794	119
Operating profit	10,081	12,311
Finance income	468	689
Finance costs	46	41
Profit before tax	10,504	12,959
Income tax expense	2,247	2,851
Profit	8,256	10,108
Profit attributable to		
Owners of parent	8,255	10,109
Non-controlling interests	0	(0)
Profit	8,256	10,108
Earnings per share		
Basic earnings per share	122.52	149.98
Diluted earnings per share	122.52	149.98

(Consolidated Statements of Comprehensive Income)

(Millions of yen)	Three months ended June 30, 2025	Three months ended June 30, 2026
Profit	8,256	10,108
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	592	(2,207)
Total of items that will not be reclassified to profit or loss	592	(2,207)
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	(200)	119
Total of items that may be reclassified to profit or loss	(200)	119
Total other comprehensive income	392	(2,088)
Comprehensive income	8,648	8,020
Comprehensive income attributable to		
Owners of parent	8,647	8,020
Non-controlling interests	0	(0)
Comprehensive income	8,648	8,020

(3) Consolidated Statements of Changes in Equity
Three months ended June 30, 2025

(Millions of yen)

	Equity attributable to owners of parent					
					Other components of equity	
	Share capital	Capital surplus	Retained earnings	Treasury shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income
Balance at beginning of period	5,174	4,491	222,640	(2,459)	(1,136)	18,318
Profit	–	–	8,255	–	–	–
Other comprehensive income	–	–	–	–	(200)	592
Comprehensive income	–	–	8,255	–	(200)	592
Dividends of surplus	–	–	(4,177)	–	–	–
Share-based payment transactions	–	22	–	–	–	–
Transfer from other components of equity to retained earnings	–	–	1,819	–	–	(1,819)
Total transactions with owners	–	22	(2,357)	–	–	(1,819)
Balance at end of period	5,174	4,514	228,538	(2,459)	(1,337)	17,091

	Equity attributable to owners of parent		Non-controlling interests	Total
	Other components of equity			
	Total	Total		
Balance at beginning of period	17,181	247,028	312	247,340
Profit	–	8,255	0	8,256
Other comprehensive income	392	392	–	392
Comprehensive income	392	8,647	0	8,648
Dividends of surplus	–	(4,177)	–	(4,177)
Share-based payment transactions	–	22	–	22
Transfer from other components of equity to retained earnings	(1,819)	–	–	–
Total transactions with owners	(1,819)	(4,154)	–	(4,154)
Balance at end of period	15,754	251,521	312	251,834

Three months ended June 30, 2026

(Millions of yen)

	Equity attributable to owners of parent					
					Other components of equity	
	Share capital	Capital surplus	Retained earnings	Treasury shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income
Balance at beginning of period	5,174	4,547	246,691	(2,440)	(587)	38,166
Profit	-	-	10,109	-	-	-
Other comprehensive income	-	-	-	-	119	(2,207)
Comprehensive income	-	-	10,109	-	119	(2,207)
Dividends of surplus	-	-	(4,178)	-	-	-
Share-based payment transactions	-	17	-	-	-	-
Transfer from other components of equity to retained earnings	-	-	-	-	-	-
Total transactions with owners	-	17	(4,178)	-	-	-
Balance at end of period	5,174	4,564	252,622	(2,440)	(468)	35,959

	Equity attributable to owners of parent		Non-controlling interests	Total
	Other components of equity			
	Total	Total		
Balance at beginning of period	37,578	291,551	319	291,871
Profit	-	10,109	(0)	10,108
Other comprehensive income	(2,088)	(2,088)	-	(2,088)
Comprehensive income	(2,088)	8,020	(0)	8,020
Dividends of surplus	-	(4,178)	-	(4,178)
Share-based payment transactions	-	17	-	17
Transfer from other components of equity to retained earnings	-	-	-	-
Total transactions with owners	-	(4,161)	-	(4,161)
Balance at end of period	35,490	295,411	318	295,730

(4) Consolidated Statements of Cash Flow

(Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from operating activities		
Profit before tax	10,504	12,959
Depreciation and amortization	1,592	1,776
Interest and dividend income	(468)	(689)
Interest expenses	22	16
Foreign exchange loss (gain)	191	(881)
Loss (gain) on sale of fixed assets	(0)	(473)
Decrease (increase) in trade and other receivables	(293)	(4,339)
Decrease (increase) in inventories	(3,226)	453
Increase (decrease) in trade and other payables	2,098	(1,959)
Increase (decrease) in retirement benefit liability	22	(398)
Other	712	2,024
Subtotal	11,155	8,487
Interest and dividends received	469	689
Interest paid	(22)	(16)
Income taxes paid	(4,803)	(7,326)
Net cash provided by (used in) operating activities	6,798	1,834
Cash flows from investing activities		
Payments into time deposits	(1,025)	(1,122)
Proceeds from withdrawal of time deposits	610	1,110
Purchase of property, plant and equipment	(876)	(1,204)
Proceeds from sale of property, plant and equipment	—	495
Purchase of intangible assets	(636)	(1,596)
Purchase of investments	(97)	(0)
Proceeds from sale and redemption of investments	2,933	—
Other	0	0
Net cash provided by (used in) investing activities	908	(2,317)
Cash flows from financing activities		
Repayments of lease liabilities	(365)	(422)
Dividends paid	(3,920)	(3,951)
Net cash provided by (used in) financing activities	(4,286)	(4,373)
Effect of exchange rate changes on cash and cash equivalents	(385)	963
Net increase (decrease) in cash and cash equivalents	3,036	(3,892)
Cash and cash equivalents at beginning of period	55,241	76,592
Cash and cash equivalents at end of period	58,277	72,699

August 6, 2026

Unit：Million yen

Brand name	Indications	Q1 (April to June)			FY2026 Forecast	
		FY2025	FY2026	Percentage change	1H (Apr to Sep)	Full-Year
Viltepso	Duchenne muscular dystrophy	5,194	5,637	8.5%	11,100	22,300
［Japan］		［1,198］	［1,206］	0.6%	［2,400］	［4,800］
［U.S.］		［3,995］	［4,431］	10.9%	［8,700］	［17,500］
Uptravi	Pulmonary arterial hypertension/ Chronic thromboembolic pulmonary hypertension	4,375	4,750	8.6%	9,200	19,200
Erleada	Prostate cancer	-	3,610	-	7,200	14,400
Fintepla	Seizures associated with Dravet syndrome/ Seizures associated with Lennox-Gastaut syndrome	887	1,480	66.9%	3,000	6,100
Vyxeos	High-risk acute myeloid leukemia	1,447	1,368	(5.4%)	3,100	6,500
Gazyva	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	1,180	1,360	15.2%	2,500	5,100
Defitelio	Sinusoidal obstruction syndrome	650	583	(10.4%)	1,300	2,600
Cialis	Erectile dysfunction	557	567	1.8%	1,000	2,000
Deramiocel (U.S.)	Duchenne muscular dystrophy cardiomyopathy	-	-	-	-	11,400
Profit in co-promotion		2,517	2,240	(11.0%)	4,500	8,600
Revenues from the licensing of industrial property rights		11,511	12,885	11.9%	27,300	53,000
Pharmaceuticals		34,163	43,256	26.6%	83,500	176,500
Functional Food		5,382	5,810	8.0%	11,500	23,500
Revenue		39,546	49,066	24.1%	95,000	200,000

(Revenue based on the NHI drug price)

Jaypirca※	Mantle cell lymphoma Chronic lymphocytic leukemia	464	1,105	138.1%	-	-

※Sales forecasts for Jaypirca are not disclosed.

Nippon Shinyaku：R＆D Pipeline List

August 06,2026

Stage	Code No. (Generic name)	Therapeutic field	Indications	Origin	Development	Target area for application
Launch Phase III	NS-065/NCNP-01 (viltolarsen)	intractable and rare diseases	Duchenne muscular dystrophy	Co-development with National Center of Neurology and Psychiatry	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Filed	CAP-1002 (deramiocel)	intractable and rare diseases	Duchenne muscular dystrophy cardiomyopathy	Partnered with Capricor Therapeutics, Inc.	Capricor Therapeutics, Inc.	U.S.
Filed	RGX-121 (clemidsogene lanparvovec)	intractable and rare diseases	Mucopolysaccharidosis Type II	Partnered with REGENXBIO Inc.	REGENXBIO Inc.	U.S.
Filed	GA101 (obinutuzumab)	intractable and rare diseases	Idiopathic nephrotic syndrome	In-licensed from Chugai Pharmaceutical Co., Ltd.	Co-development with Chugai Pharmaceutical Co., Ltd.	Japan
Preparation for BLA	Tadekinig alfa	intractable and rare diseases	NLRC4 and XIAP mutations	AB2 Bio Ltd.	AB2 Bio Ltd.	U.S.
Phase III	ZX008 (fenfluramine hydrochloride)	intractable and rare diseases	CDKL5 deficiency disorder	Distribution partnership with UCB S.A. (formerly known as Zogenix, Inc.)	UCB S.A. (formerly known as Zogenix, Inc.)	Japan
Phase III	GA101 (obinutuzumab)	intractable and rare diseases	Lupus nephritis Extra renal lupus	In-licensed from Chugai Pharmaceutical Co., Ltd.	Co-development with Chugai Pharmaceutical Co., Ltd.	Japan
Phase III	CAP-1002 (deramiocel)	intractable and rare diseases	Duchenne muscular dystrophy	Partnered with Capricor Therapeutics, Inc.	Capricor Therapeutics, Inc.	U.S.
Phase III	LY3527727 (pirtobrutinib)	hematologic malignancies	Mantle cell lymphoma Chronic lymphocytic leukemia	Alliance agreement in Japan with Eli Lilly Japan K.K.	Eli Lilly Japan K.K.	Japan
Phase III	NS-304 (selexipag)	cardiovascular	Arteriosclerosis obliterans	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan
Preparation for Phase III	ZX008 (fenfluramine hydrochloride)	intractable and rare diseases	Rett syndrome	Distribution partnership with UCB S.A. (formerly known as Zogenix, Inc.)	UCB S.A. (formerly known as Zogenix, Inc.)	Japan
Phase II	NS-580	gynecology	Endometriosis	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan
		urological diseases	Chronic prostatitis / Chronic pelvic pain syndrome			
Phase II	NS-089/NCNP-02 (brogidirsen)	intractable and rare diseases	Duchenne muscular dystrophy	Co-development with National Center of Neurology and Psychiatry	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Phase II	NS-229	intractable and rare diseases	Eosinophilic granulomatosis with polyangiitis	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Preparation for Phase II	NS-035	intractable and rare diseases	Fukuyama congenital muscular dystrophy	Co-development with Kobe University	Nippon Shinyaku Co., Ltd.	Japan
Preparation for Phase II	NS-863	cardiovascular	Pulmonary arterial hypertension Pulmonary hypertension associated with interstitial lung disease	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Preparation for Phase II	NS-025	urological diseases	Urological diseases	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan
		autoimmune disease	Xerostomia (dry mouth) associated with Sjögren's disease		Aquelys Therapeutics, Inc.	Japan/U.S.
Phase I/II	NS-050/NCNP-03	intractable and rare diseases	Duchenne muscular dystrophy	Co-development with National Center of Neurology and Psychiatry	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Phase I/II	ATSN-101	intractable and rare diseases	GUCY2D-associated Leber congenital amaurosis	In-licensed from Atsena Therapeutics, Inc.	Atsena Therapeutics, Inc.	U.S.
Phase I/II	RGX-111	intractable and rare diseases	Mucopolysaccharidosis Type I	Partnered with REGENXBIO Inc.	REGENXBIO Inc.	U.S.
Phase I	NS-917 (radgocitabine)	hematologic malignancies	Relapsed/refractory acute myeloid leukemia	In-licensed from Delta-Fly Pharma, Inc.	Nippon Shinyaku Co., Ltd.	Japan
Phase I	NS-245	inflammatory diseases	Inflammatory diseases	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan